Press Releases | Regeneron Pharmaceuticals Inc.
WEBDupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD) Sep 26. Regeneron to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on October 31, 2024. Sep 20.
Regeneron Announces Formation of Regeneron Cell Medicines …
WEBJan 30, 2024 — Regeneron Announces Formation of Regeneron Cell Medicines with the Acquisition of 2seventy bio Platforms and Preclinical and Clinical Programs. Regeneron to assume full development and commercialization rights for 2seventy bio’s preclinical and clinical stage cell therapy pipeline.
Novel Regeneron Bispecific Antibodies Show Encouraging Anti …
WEBNovel Regeneron Bispecific Antibodies Show Encouraging Anti-tumor Activity in Two Advanced Solid Tumors. First-in-class Phase 1 data presented at ESMO for ubamatamab (REGN4018; MUC16xCD3) in recurrent ovarian cancer and REGN5093 (METxMET) in MET-altered advanced non-small cell lung cancer.
INVESTORS & MEDIA - Regeneron Pharmaceuticals Inc.
WEBAug 1, 2024 — Regeneron is shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling Regeneron to identify innovative targets and complementary approaches to potentially treat or cure diseases.
INVESTORS & MEDIA - newsroom.regeneron.com
WEB3 days ago — Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Following recent approvals in the EU and China, the U.S. approval is based on two landmark Phase 3 trials that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung ...
Regeneron Announces Encouraging Topline Phase 2 Data of High …
WEBAug 24, 2021 — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA ® …
Regeneron, Sanofi's Dupixent Get FDA Approval For Chronic
WEB3 days ago — (RTTNews) - Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY), Friday announced that the U.S. Food and Drug Administration has approved Dupixent as an add-on maintenance treatment of adults ...
Regeneron, Sanofi Get FDA OK of Dupixent for COPD — Update
WEB3 days ago — RBC said it sees an ultimate world-wide COPD sales opportunity topping $6.5 billion, bringing overall Dupixent sales to more than $26 billion at their peak. Tarrytown, N.Y., biotechnology company ...
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEB3 days ago — For Regeneron, which splits U.S. Dupixent revenue with Sanofi, the COPD approval is a needed boost. The company lost nearly $14 billion of its market value earlier this week after a setback in a ...
Regeneron to Acquire Decibel Therapeutics, Strengthening Gene …
WEBAug 9, 2023 — Proposed acquisition builds on existing collaboration between Decibel and Regeneron, will accelerate and further resource key gene therapy programs for hearing loss. Decibel’s lead investigational gene therapy DB-OTO, designed to provide hearing to people with otoferlin-related hearing loss, is in its first clinical trial.